Anticancer agent 281 (TFA)
Anticancer agent 280 TFA (Compound 65) is an anti-cancer agent targeting triple-negative breast cancer (TNBC) . Anticancer agent 280 TFA exhibits IC50 values of Anticancer agent 280 TFA for MDA-MB-231, MDA-MB-231/LM2-4, Jurkat, and MCF-7 of 7.1, 11.65, 6.99, and 21.51 μM respectively. Anticancer agent 280 TFA can cause significant arrest of cells in the S phase and induce cell apoptosis. Anticancer agent 280 TFA can be used for the study of TNBC[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis
Related Pathways
Apoptosis
Field of Research
Cancer
Smiles
FC1=CC2=C(N(C3CC3)C=C(C(N[C@@H](CC(C)C)C(NC4=CC=C([N+]([O-])=O)C=C4Cl)=O)=O)C2=O)C=C1N5CC[NH2+]CC5.FC(F)(F)C([O-])=O
Molecular Formula
C31H33ClF4N6O7
Molecular Weight
713.08
References & Citations
[1]Azzman N, et al. Novel 4-quinolone derivative inflicted cytotoxicity via intrinsic apoptotic pathway activation on human metastatic triple-negative breast cancer cells. Bioorg Chem. 2025 Oct;165:109033.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
I8440-03R-APC 200 µL
IL18RAP, NT (CD218b, CDw218b, CD218 Antigen-like Family Member B, Interleukin-1 Receptor 7, IL-1R-7, IL-1R7, Accessory Protein-like, AcPL, IL-1R Accessory Protein-like, IL-1RAcPL, Interleukin-18 Receptor beta, IL-18R-beta, IL-18Rbeta, Interleukin-18 Receptor Accessory Protein-like, Interleukin-18 Receptor Accessory Protein, IL-18 Receptor Accessory Protein, IL-18RAcP, IL1R7) (APC) discontinued
Sign In for Pricing
View Details 
